Its a different private company in Isreal. The process seems the same though: Amino Acid Derivatives. BZYR owns the patents in the United States so we have an upper hand. Either BZYR get bought out or the process gets more well known and the FDA can no longer ignore the results and approves further trials with BZYR. Or bzyr could continue treating under the "Right to Try Act" that was just passed last year or the "orphan drug" program as well. : ) Lots of possibilities it seems.
News 
Market Data 
Discover 
